Table of Contents Table of Contents
Previous Page  180 / 916 Next Page
Show Menu
Previous Page 180 / 916 Next Page
Page Background


25th European Congress of Psychiatry / European Psychiatry 41S (2017) S170–S237

Health care should be improved to provide better response to this

type of patients.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.


Effects of smartphone-based memory

training for older adults with

subjective memory complaints

M.S. Shin

1 ,

, S .J.


2 , S. S


3 , J.H

. Lee

3 , M.

J. Song



Seoul National University College of Medicine, Department of

Psychiatry and Behavioral Science, Seoul, Republic of Korea


Seoul National University College of Medicine, Department of

Clinical Medical Sciences, Seoul, Republic of Korea


Seoul National University Hospital, Department of Neuropsychiatry,

Seoul, Republic of Korea

Corresponding author.


Brain health has garnered increasing attention as a

requisite condition for healthy aging. The rapid growth in mobile

health and increasing smartphone ownership among older adults

has paved the way for smartphones to be utilized as effective tools

for improving mental fitness.


There are few studies that have explored the efficacy

of smartphone-based cognitive training. The present study exam-

ined the memory-enhancing effects of smartphone-based memory

training for older adults.


We explored whether newly developed application

“Smartphone-based brain Anti-aging and memory Reinforcement

Training (SMART)” improved memory performance in older adults

with subjective memory complaints.


A total of 53 adults (mean age: 59.3 years) were ran-

domised into either one of two smartphone-based intervention

groups (SMART vs. Fit Brains


) or a wait-list group. Participants

in the intervention groups underwent 15–20minutes of training

per day, five days per week for 8weeks. We used objective cogni-

tive measures to evaluate changes with respect to four domains:

attention, memory, working memory (WM), and executive func-

tion (inhibition, fluency, etc.). In addition, we included self-report

questionnaires to assess levels of subjective memory complaints.


The performance on WM test increased significantly in

the SMART group (


[17] = 6.27,


< 0.0001) but not in the control

groups. Self-reports of memory contentment, however, increased

in the Fit Brains


group only (


[18] = 2.12,


= 0.048).


Use of an 8-week smartphone-based memory train-

ing program may improve working memory function in older

adults. However, objective improvement in performance does not

necessarily lead to decreased subjective memory complaints.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.


Drug–drug interactions between

antibiotics and

psychopharmaceuticals in Slovenian

nursing homes: A retrospective

observational cohort study from a

national perspective

M. Stuhec

1 ,

, P. Ines


, D. Stepan


, U. Lea


, M. Petek Ster



B. Beovi´c



Faculty of Pharmacy, Biopharmacy and Pharmacokinetics,

Ljubljana, Slovenia


Faculty of Pharmacy Ljubljana, Biopharmacy and Pharmacokinetics,

Ljubljana, Slovenia


Faculty of Medicine Ljubljana, Department of Family Medicine,

Ljubljana, Slovenia


Faculty of Medicine Ljubljana, Department of Infectious Diseases,

Ljubljana, Slovenia

Corresponding author.


Drug–drug interactions (DDIs) between antibiotics

and psychopharmaceuticals in large national data have not been

described yet.


In most European countries, there is no national data

on DDIs in patients within nursing homes.


To present themost important DDIs in the Slovenian nursing

homes to avoid serious DDIs in the future.


A retrospective study was carried in 2015 and with 233

patient on antibiotic treatment. All study data from the patients’

records were obtained from the patients’ charts. DDIs were deter-

mined by different interaction classeswith LexicompOnline



version and only X (major interactions) and D (minor interactions)

were included.


A total of 233 patients (age = 83.5, SD = 9.8) were treated

with antibiotics (only 2without psychopharmaceuticals). The num-

ber of patients with at least 1 interaction was: 72 (30.9%) for X and

172 (73.8%) for D and the average number of medication/patient

was 10.9 (SD = 3.9). Twenty-seven patients (11.5%) were treated

with at least 1 X DDIs s (17 patients ciprofloxacin, 6 moxifloxacin,

3 azithromycin and 1 levofloxacin). Quetiapine and ciprofloxacin

was most frequent DDIs occured in 12 patients. Twenty-seven

DDIs were pharmacodynamic (QTc prolongation) and 3 pharma-

cokinetic (ciprofloxacin-tizanidine, ciprofloxacin and duloxetine in

2 patients;


= 3). Quetiapine was most frequent prescribed psy-

chopharmaceutical in X DDIs.


DDIs between these two groups are seen very often.

If an antidepressant should be used in these patients, we recom-

mend sertraline instead of escitalopram and venlafaxine instead of

duloxetine and mirtazapine instead of quetiapine. We also recom-

mend a use of penicilins instead of ciprofloxacin and azithromycin.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.


Efficacy of rivastigmine on loss of

appetite in patients with Alzheimer’s


N. Tsuno

, T. Mori , Y. Nakamura

Kagawa University, Department of Neuropsychiatry, Miki-cho,

Kita-gun, Japan

Corresponding author.


It has been said that nearly 30% of the patients with

Alzheimer’ disease (AD) manifest loss of appetite, which might

increase cognitive impairments and the incidence of neuropsy-

chiatric symptoms, and malnutrition. As a result, a vicious cycle

decreases functionality and quality of life in patients with AD.

Cholinesterase inhibitors (ChEIs) is the first-line drugs in the treat-

ment of AD. On the one hand, appetite or weight loss can be seen

due to gastrointestinal side effects in the treatment of ChEIs. On the

other hand, there are some reports in clinical-settings that patients

with AD treated with rivastigmine transdermal patch showed the

improvement of appetite loss.


To evaluate the efficacy of rivastigmine transdermal

patch in AD patients with poor appetite.


In this 16-weeks, multicenter prospective study,

patients with mild to moderate AD, who manifest loss of appetite

and began to receive rivastigmine transdermal patch therapy, were

enrolled. The amount of food, total time-eating, body weight, Mini

Mental State Examination (MMSE) and Neuropsychiatric Inventory

(NPI) were evaluated.